TST 010
Alternative Names: TST-010Latest Information Update: 21 Apr 2023
At a glance
- Originator Transcenta Holding
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Regulatory T-lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 18 Apr 2023 Pharmacodynamics data from a preclinical study in Solid tumours released by Transcenta Holding
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Solid tumors presented at the Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 24 Mar 2022 TST 010 is available for licensing as of 24 Mar 2022. http://www.transcenta.com/partnership